Treatment and Management of Idiopathic Pulmonary Fibrosis
For confirmed IPF, initiate antifibrotic therapy with either nintedanib or pirfenidone immediately at diagnosis, as both medications slow disease progression and should be considered standard pharmacological treatment. 1
Pharmacological Management
Antifibrotic Therapy
The 2022 ATS/ERS/JRS/ALAT guidelines establish that both nintedanib and pirfenidone are the cornerstone of IPF treatment 1. These medications:
- Slow the rate of FVC decline (the primary measure of disease progression)
- Do not cure IPF but meaningfully impact disease trajectory
- Should be started at diagnosis rather than waiting for progression 2, 3
Key consideration: Choose between these agents based on side effect profile and patient tolerance, as both have similar efficacy in slowing progression 2.
Managing Antifibrotic Side Effects
Both medications cause predominantly gastrointestinal adverse events 1:
Nintedanib causes:
- Diarrhea (2.8× increase)
- Nausea (3.1× increase)
- Vomiting (3.6× increase)
- Weight loss (3.7× increase)
- Elevated liver enzymes (AST 3.2×, ALT 3.6×)
- Treatment discontinuation (1.9× increase) 1
Management strategy: Use dose reductions (7.9× more common with nintedanib) and symptomatic treatment rather than discontinuing therapy 1, 2.
Monitoring Protocol
Regular Assessment Schedule
Monitor every 3-6 months with 1:
- Pulmonary function tests (FVC and DLCO) every 4-6 months
- 6-minute walk test every 4-6 months
- Annual HRCT if clinical suspicion of worsening or lung cancer risk
- HRCT as needed for suspected acute exacerbation
Defining Disease Progression
Progression occurs when at least 2 of 3 criteria are met within one year 1:
- Worsening respiratory symptoms
- FVC decline >5% predicted OR DLCO decline >10% predicted
- Radiological progression (increased traction bronchiectasis, new ground-glass opacity with traction bronchiectasis, new/increased honeycombing, increased reticular abnormality)
Non-Pharmacological Management
Essential Interventions
- Oxygen supplementation when hypoxemic 1
- Pulmonary rehabilitation to maintain functional capacity 1, 4
- Smoking cessation if applicable 2
- Vaccinations (pneumococcal, influenza) 2
Comorbidity Management
Evaluate and treat 1:
- Gastroesophageal reflux disease
- Pulmonary hypertension
- Obstructive sleep apnea
- Lung cancer screening
Lung Transplantation Referral
Refer at diagnosis if increased mortality risk 1. Do not wait for severe progression, as transplant evaluation is lengthy and patients may deteriorate while waiting.
High-risk features requiring immediate referral:
- Rapid FVC decline
- Severe baseline impairment
- Younger patients who are transplant candidates
Acute Exacerbation Management
Use corticosteroids for acute exacerbations 1. However, note that:
- Mechanical ventilation is NOT recommended for the majority of patients with respiratory failure 1
- This represents a critical advance directives discussion point
Palliative Care Integration
Integrate palliative care early for symptom management 1, 4:
- Dyspnea control
- Cough suppression
- Anxiety management
- Goals of care discussions
This should occur concurrently with disease-modifying therapy, not as an end-of-life measure 4.
Clinical Trial Enrollment
Patients should be informed of available clinical trials at all disease stages 1, as IPF remains ultimately fatal despite current therapies and novel treatments are actively being investigated 5.
Critical Pitfalls to Avoid
- Delaying antifibrotic therapy: Start at diagnosis, not after observing progression 1
- Discontinuing antifibrotics for GI side effects: Manage with dose reduction and symptomatic treatment first 2
- Late transplant referral: Refer high-risk patients immediately at diagnosis 1
- Using mechanical ventilation routinely: Generally contraindicated in respiratory failure 1
- Assuming stability means no progression: FVC stability does not predict future stability; continue frequent monitoring 6